Many patients newly diagnosed with castration-resistant prostate cancer (CRPC) may be interested in participating in a new registry study known as the TRUMPET study, which has just started to enroll patients and is sponsored by Astellas and Medivation (the developers and marketers of enzalutamide/Xtandi). … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: care, patterns, registry, study, trial, TRUMPET | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 